DRUG · Unmapped registry intervention
eribulin mesylate + erlotinib
Find medicine records ·
Find other trials using this name
Clinical trial
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
NCT01104155
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
eribulin mesylate + erlotinib
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Eisai Inc.lead sponsor
Mapped research locations
PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1SeoulSouth Korea1BirminghamAlabama, United States1PortlandOregon, United States1Washington D.C.District of Columbia, United States1AuroraColorado, United States1DenverColorado, United States1DetroitMichigan, United States1TaipeiTaiwan1Las VegasNevada, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01104155 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.